Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Eakin, Katharine ^a   Li, Yazhou ^b   Chiang, Yung Hsiao ^c,d   Hoffer, Barry J ^a   Rosenheim, Hilary ^a   Greig, Nigel H ^b   Miller, Jonathan P ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUTAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN NERVE CELL; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MORRIS WATER MAZE TEST; NEUROBLASTOMA CELL; NEUROPROTECTION; NONHUMAN; RAT; TRAUMATIC BRAIN INJURY;

ANIMALS; BRAIN INJURIES; CELL DEATH; CELL LINE, TUMOR; COGNITION; DRUG REPOSITIONING; HUMANS; HYPOGLYCEMIC AGENTS; MALE; NEURONS; NEUROPROTECTIVE AGENTS; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION; VENOMS;

EID: 84891464127     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082016     Document Type: Article

References (58)

1. Faul MD, Xu L, Wald M, Coronado V (2010) Traumatic brain injury in the United States: Emergency department visits, hospitalizations, and deaths. Atlanta (GA): Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. pp. 2002-2006.
2. Coronado VG, Xu L, Basavaraju SV, McGuire LC, Wald MM et al. (2011) Centers for Disease Control and Prevention (CDC). Surveillance for traumatic brain injury-related deaths - United States, 1997-2007. MMWR Surveill Summ 6:60(5): 1-32.
3. Goldstein M (1990) Traumatic brain injury: a silent epidemic (Editorial) Ann Neurol 27: 327 doi:10.1002/ana.410270315. PubMed: 2327740.
4. CDC (2010) Injury, prevention, & control: traumatic brain injury. Center for Disease Control and Prevention. Available online at: http://www.cdc.gov/traumaticbraininjury/statistics.html.
5. Tagliaferri F, Compagnone C, Korsic M, Servadei F, Kraus J (2006) Systematic review of brain injury epidemiology in Europe. Acta-Neurochir (Wien) 148: 255-268. doi:10.1007/s00701-005-0651-y.
6. Susman M, DiRusso SM, Sullivan T, Risucci D, Nealon P et al. (2002) Traumatic brain injury in the elderly: increased mortality and worse functional outcome at discharge despite lower injury severity. J Trauma 53: 219-223. doi:10.1097/00005373-200208000-00004. PubMed: 12169925.
7. Comper P, Bisschop SM, Carnide N, Tricco A (2005) A systematic review of treatments for mild traumatic brain injury. Brain Inj 19: 863-880. doi:10.1080/02699050400025042. PubMed: 16296570.
8. Hesdorffer DC, Rauch SL, Tamminga CA (2009) Long-term psychiatric outcomes following traumatic brain injury: a review of the literature. J Head Trauma Rehabil 24: 452-459. doi:10.1097/HTR.0b013e3181c133fd. PubMed: 19940678.
9. Rutland-Brown W, Langlois JA, Thomas KE, Xi YL (2003) Incidence of traumatic brain injury in the United States. J Head Trauma Rehabil 21(6): 544-548.
10. Morganti-Kossman MC, Lenzlinger PM, Hans V, Stahel P, Csuka E et al. (1997) Production of cytokines following braininjury: beneficial and deleterious for the damaged tissue. Mol Psychiatry 2(2): 133-136. doi: 10.1038/sj.mp. 4000227. PubMed: 9106236.
11. Farkas O, Povlishock JT (2007) Cellular and subcellular change evoked by diffuse traumatic brain injury: a complex web of change extending far beyond focal damage. Prog-Brain Res 161: 43-59.
12. Lenzlinger PM, Hans VH, Jöller-Jemelka HI, Trentz O, Morganti-Kossmann MC, et (2001) Markers for cell-mediated immune response are elevated in cerebrospinal fluid and serum after severe traumatic brain injury in humans. J Neurotrauma. 18(5): 479-489. doi: 10.1089/089771501300227288. PubMed: 11393251.
13. Raghupathi R, Graham DI, McIntosh TK (2000) Apoptosis after traumatic brain injury. J Neurotrauma 17: 927-938. doi:10.1089/neu.2000.17.927. PubMed: 11063058.
14. Tweedie D, Milman A, Holloway HW, Li Y, Harvey BK et al. (2007) Apoptotic and behavioral sequelae of mild brain trauma in mice. J Neurosci Res 85: 805-815. doi:10.1002/jnr.21160. PubMed: 17243171.
15. Gallwitz B (2011) Glucagon-like peptide-1 analogues for type 2 diabetes mellitus: current and emerging agents. Drugs 71: 1675-1688. doi:10.2165/ 11592810-000000000-00000. PubMed: 21902291.
16. Lovshin JA, Drucker DJ (2009) Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 5: 262-269. doi:10.1038/nrendo. 2009.48. PubMed: 19444259.
17. Kastin AJ, Akerstrom V (2003) Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 27: 313-318. doi:10.1038/sj.ijo.0802206. PubMed: 12629557.
18. Salcedo I, Tweedie D, Li Y, Greig NH (2012) Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol 166: 1586-1599. doi:10.1111/j.1476-5381.2012.01971.x. PubMed: 22519295.
19. Heile AM, Wallrapp C, Klinge PM, Samii A, Kassem M, Silverberg G, Brinker T (2009) Cerebral transplantation of encapsulated mesenchymal stem cells improves cellular pathology after experimental traumatic brain injury. Neuroscience Lett 463(3): 176-181.
20. Perry T, Greig NH (2003) The glucagon-like peptides: a double-edged therapeutic sword? Trends Pharmacol Sci 24(7): 377-383. doi:10.1016/S0165- 6147(03)00160-3. PubMed: 12871671.
21. Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D et al. (2009) GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A 106: 1285-1290. doi:10.1073/pnas.0806720106. PubMed: 19164583.
22. Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA et al. (2010) GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 19: 1205-1219. PubMed: 20308787.
23. Chen H, Yoshioka H, Kim GS, Jung JE, Okami N et al. (2011) Oxidative stress in ischemic brain damage: mechanisms of cell death and potential molecular targets for neuroprotection. Antioxid Redox Signal 14(8): 1505-1517. doi:10.1089/ars.2010.3576. PubMed: 20812869.
24. Luciani P, Deledda C, Benvenuti S, Cellai I, Squecco R et al. (2010) Differentiating effects of the glucagon-like peptide-1 analogue exendin-4 in a human neuronal cell model. Cell Mol Life Sci 67(21): 3711-3723. doi:10.1007/s00018-010-0398-3. PubMed: 20496097.
25. Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH (2002) Protection and reversal of excitotoxic neuronal damage by glucagonlike peptide-1 and exendin-4. J Pharmacol Exp Ther 302: 881-888. doi: 10.1124/jpet.102.037481. PubMed: 12183643.
26. Gilman CP, Perry T, Furukawa K, Grieg NH, Egan JM et al. (2003) Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons. J Neurochem 87(5): 1137-1144. doi:10.1046/j.1471-4159.2003.02073.x. PubMed: 14622093.
27. Rachmany L, Tweedie D, Li Y, Rubovitch V, Holloway HW et al. (2012) Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. Age (Dordr).[Epub ahead of print].
28. Tweedie D, Rachmany L, Rubovitch V, Lehrmann E, Zhang Y et al. (2013) Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice. Exp Neurol 239: 170-182. doi:10.1016/j.expneurol.2012.10.001. PubMed: 23059457.
29. Marklund N, Hillered L (2011) Animal modeling of traumatic brain injury in preclinical drug development: where do we go from here? Br J Pharmacol 164: 1207-1229. doi:10.1111/j.1476-5381.2010.01163.x. PubMed: 21175576.
30. Leker RR, Shohami E, Constantini S (2002) Experimental models of head trauma. Acta Neurochir Suppl 83: 49-54. PubMed: 12442621.
31. Li Y, Tweedie D, Mattson MP, Holloway HW, Greig NH (2010) Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J Neurochem 113: 1621-1631. PubMed: 20374430.
32. Hinzman JM, Thomas TC, Burmeister JJ, Quintero JE, Huettl P et al. (2010) Diffuse brain injury elevates tonic glutamate levels and potassium-evoked glutamate release in discrete brain regions at two days post-injury: an enzyme-based microelectrode array study. J Neurotrauma 27(5): 889-899. doi:10.1089/neu.2009.1238. PubMed: 20233041.
33. Mehta A, Prabhakar M, Kumar P, Deshmukh R, Sharma PL (2013) Excitotoxicity: bridge to various triggers in neurodegenerative disorders. Eur J Pharmacol 698(1-3): 6-18. doi:10.1016/j.ejphar.2012.10.032. PubMed: 23123057.
34. Dixon CE, Lyeth BG, Povlishock JT, Findling RL, Hamm RJ et al. (1987) A fluid percussion model of experimental brain injury in the rat. J Neurosurg 67: 110-119. doi:10.3171/jns.1987.67.1.0110. PubMed: 3598659.
35. Li Y, Chigurupati S, Holloway HW, Mughal M, Tweedie D et al. (2012) Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PLOS ONE 7(2): e32008. doi:10.1371/journal.pone. 0032008. PubMed: 22384126.
36. Li H, Lee CH, Yoo KY, Choi JH, Park OK et al. (2010) Chronic treatment of exendin-4 affects cell proliferation and neuroblast differentiation in the adult mouse hippocampal dentate gyrus. Neurosci Lett 486: 38-42. doi:10.1016/j.neulet.2010.09.040. PubMed: 20854877.
37. Morris RG, Garrud P, Rawlins JN, O'Keefe J (1982) Place navigation impaired in rats with hippocampal lesions. Nature 297 (5868): 681-683. doi:10.1038/297681a0. PubMed: 7088155.
38. Tweedie D, Rachmany L, Rubovitch V, Zhang Y, Becker KG et al. (2013) Changes in mouse cognition and hippocampal gene expression observed in a mild physical- and blast-traumatic brain injury. Neurobiol Dis 54: 1-11. doi:10.1016/j.nbd.2013.02.006. PubMed: 23454194.
39. Campbell JE, Drucker DJ (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17: 819-837. doi:10.1016/j.cmet.2013.04. 008. PubMed: 23684623.
40. Atkins CM, Oliva AA Jr, Alonso OF, Pearse DD, Bramlett HM et al. (2007) Modulation of the cAMP signaling pathway after traumatic brain injury. Exp Neurol 208(1): 145-158. doi:10.1016/j.expneurol. 2007.08.011. PubMed: 17916353.
41. Lyeth BG, Jenkins LW, Hamm RJ, Dixon CE et al. (1990) Prolonged memory impairment in the absence of hippocampal cell death following traumatic brain injury in the rat. Brain Res 526(2): 249-258. doi:10.1016/0006-8993(90)91229-A. PubMed: 2257484.
42. Hamm RJ, Lyeth BG, Jenkins LW, O'Dell DM, Pike BR (1993) Selective cognitive impairment following traumatic brain injury in rats. Behav Brain Res 59: 169-173. doi:10.1016/0166-4328(93)90164-L. PubMed: 8155285.
43. Finset A, Anke AW, Hofft E, Roaldsen KS, Pillgram-Larsen J et al. (1999) Cognitive performance in multiple trauma patients 3 years after injury. Psychosom Med 61(4): 576-583. PubMed: 10443768.
44. Henninger N, Dützmann S, Sicard KM, Kollmar R, Bardutzky J et al. (2005) Impaired spatial learning in a novel rat model of mild cerebral concussion injury. Exp Neurol 195(2): 447-457. doi:10.1016/j.expneurol.2005.06. 013. PubMed: 16084512.
45. Zohar O, Schreiber S, Getslev V, Schwartz JP, Mullins PG et al. (2003) Closed-head minimal traumatic brain injury produces long-term cognitive deficits in mice. Neuroscience 118(4): 949-955. doi:10.1016/S0306-4522(03)00048-4. PubMed: 12732240.
46. Scheff SW, Baldwin SA, Brown RW, Kraemer PJ (1997) Morris Water Maze deficits in rats following traumatic brain injury: lateral controlled cortical impact. J Neurotrauma 14(9): 615-627. doi:10.1089/neu.1997.14.615. PubMed: 9337124.
47. Smith DH, Okiyama K, Thomas MJ, Claussen B, McIntosh TK (1991) Evaluation of memory dysfunction following experimental brain injury using the Morris Water Maze. J Neurotrauma 8(4): 259-269. doi: 10.1089/neu.1991.8.259. PubMed: 1803034.
48. Schwarzbold ML, Rial D, De Bem T, Machado DG, Cunha MP et al. (2010) Effects of traumatic brain injury of different severities on emotional, cognitive, and oxidative stress-related parameters in mice. J Neurotrauma 27(10): 1883-1893. doi:10.1089/neu.2010.1318. PubMed: 20649482.
49. Washington PM, Forcelli PA, Wilkins T, Zapple DN, Parsadanian M et al. (2012) The effect of injury severity on behavior: a phenotypic study of cognitive and emotional deficits after mild, moderate, and severe controlled cortical impact injury in mice. J Neurotrauma 29(13): 2283-2296. doi:10.1089/neu.2012.2456. PubMed: 22642287.
50. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M et al. (2008) Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomized, open-label, non-inferiority study. Lancet 372: 1240-1250. doi:10.1016/S0140-6736(08)61206-4. PubMed: 18782641.
51. Göke R, Larsen PJ, Mikkelsen JD, Sheikh SP (1995) Identification of specific binding sites for glucagon-like peptide-1 on the posterior lobe of the rat pituitary. Neuroendocrinology 62: 130-134. doi:10.1159/000126997. PubMed: 8584112.
52. Göke R, Larsen PJ, Mikkelsen JD, Sheikh SP (1995) Distribution of GLP-1 binding sites in the rat brain: Evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 7: 2294-2300. doi:10.1111/j.1460-9568. 1995.tb00650.x. PubMed: 8563978.
53. Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 2131-2157. doi:10.1053/j.gastro.2007.03.054. PubMed: 17498508.
54. Hölscher C (2010) The role of GLP-1 in neuronal activity and neurodegeneration. Vitam Horm 84: 331-354. doi:10.1016/B978-0-12-381517-0.00013- 8. PubMed: 21094907.
55. Holst JJ, Burcelin R, Nathanson E (2011) Neuroprotective properties of GLP-1: theoretical and practical applications. Curr Med Res Opin 27: 547-558. doi:10.1185/03007995.2010.549466. PubMed: 21222567.
56. Bak AM, Egefjord L, Gejl M, Steffensen C, Stecher CW et al. (2011) Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes. Expert Opin Ther Targets 10: 1153-1162. PubMed: 21749267.
57. Martin B, Golden E, Carlson OD, Pistell P, Zhou J et al. (2009) Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes 58: 318-328. PubMed: 18984744.
58. Perry T, Holloway HW, Weerasuriya A, Mouton PR, Duffy K et al. (2007) Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 203: 293-301. doi:10.1016/j.expneurol.2006.09.028. PubMed: 17125767.